Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.

Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. <li /> Increased the midpoint of o ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...